Information Provided By: 
Fly News Breaks for September 5, 2017
MDXG
Sep 5, 2017 | 13:34 EDT
Piper Jaffray analyst Matt O'Brien noted the strong momentum MiMedx saw in the first half has continued into Q3. While the company said it sees beating its Q3 revenue guidance but left its full year view unchanged for now, he "fully" expects guidance will be raised with its Q3 report. O'Brien recommends investors become increasingly aggressive on pullbacks in MiMedx and keeps an Overweight rating on the shares.
News For MDXG From the Last 2 Days
There are no results for your query MDXG
